30th July 2015
Company Announcements Office
Australian Stock Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000
Dear Sir/Madam,
Re: Appendix 4C - Quarterly Report
Please refer to the ‘Appendix 4C’ attached for details of financial results for the fourth quarter and full year ended 30 June 2015 for the Group.
• Revenue for the quarter was $2.9M, up 16% from the previous quarter and 36% from the corresponding period.
• Full year gross revenue up 29% to $10.2M
• Cash balance at 30 June 2015 of $24M (30 June 2014 $19.6M)
• CardioCel® now launched in the USA, Europe, Canada, Singapore and Hong Kong
• CardioCel® used in over 90 centres globally, over 70 centres added in the past 12 months
• Expansion of the ADAPT tissue portfolio including for the repair of dura mater
•Continued therapeutic vaccine clinical development
A successful year: CardioCel® sales grow; therapeutic vaccine pipeline progresses
Admedus had a strong 12 months, with net sales for the year up 29% to $10.2M, from $7.9M in the previous period. Global usage of CardioCel® continues to grow steadily, with sales increasing each quarter. For the year ending 30 June 2015, Admedus had total CardioCel® sales of $2.57M.
Total income for the Group was $11.4M, which included a tax rebate of $1.1M and grants of $148,000. The closing cash balance at the end of the period was $24M following a placement of shares in March that raised $28M.
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
Company Announcements Office
Australian Stock Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000
Dear Sir/Madam,
Re: Appendix 4C - Quarterly Report
Please refer to the ‘Appendix 4C’ attached for details of financial results for the fourth quarter and full year ended 30 June 2015 for the Group.
• Revenue for the quarter was $2.9M, up 16% from the previous quarter and 36% from the corresponding period.
• Full year gross revenue up 29% to $10.2M
• Cash balance at 30 June 2015 of $24M (30 June 2014 $19.6M)
• CardioCel® now launched in the USA, Europe, Canada, Singapore and Hong Kong
• CardioCel® used in over 90 centres globally, over 70 centres added in the past 12 months
• Expansion of the ADAPT tissue portfolio including for the repair of dura mater
•Continued therapeutic vaccine clinical development
A successful year: CardioCel® sales grow; therapeutic vaccine pipeline progresses
Admedus had a strong 12 months, with net sales for the year up 29% to $10.2M, from $7.9M in the previous period. Global usage of CardioCel® continues to grow steadily, with sales increasing each quarter. For the year ending 30 June 2015, Admedus had total CardioCel® sales of $2.57M.
Total income for the Group was $11.4M, which included a tax rebate of $1.1M and grants of $148,000. The closing cash balance at the end of the period was $24M following a placement of shares in March that raised $28M.
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
